Send2Press Newswire
Wed, 01 Sep 2010 21:00:19 GMT
Reaction Biology Receives NCI Grant Award for Epigenetic Platform
MALVERN, Pa., Aug. 11 (SEND2PRESS NEWSWIRE) -- Reaction Biology Corporation ("RBC") announced today that it has been awarded a Phase II SBIR grant from the National Cancer Institute to expand the reach of its Methyltransferase HotSpotSM drug discovery platform. The $1.2 million, two-year grant will help fund an expansion of RBC's methyltransferase screens from 14 to 35 or more.
RBC's HotSpot technology is an ultra-low volume tritium-based assay platform that provides gold-standard methyltransferase inhibition data.
The technology is offered as a screening service, allowing clients to avoid operational issues related to dealing with radioisotope management, and quickly find productive lead candidates.
RBC Chief Technology Officer Haiching Ma said, "Epigenetic mechanisms are increasingly recognized as fundamental to several cancers and many other diseases. Up until now, there has been no cost-effective way to do large-scale methyltransferase screening and profiling. We hope that RBC's ability to fill this unmet need will speed the discovery of new drugs in this area."
Based in Malvern, PA, RBC specializes in providing high quality biochemical enzyme assay data, using ultra-low volumes and proprietary methods. RBC has provided its services to over 190 customers worldwide, including large pharmaceutical, biotech, government, and academic labs.
RBC's Kinase HotSpotSM platform is a widely used service for providing high quality low-cost kinase screening data worldwide. The company also provides HDAC, protease, and other screening services, as well as custom assay development and partnerships.
For more information, visit: www.reactionbiology.com.
NEWS SOURCE: Reaction Biology Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Reaction Biology Corporation, Drugs and Pharmaceuticals, Send2Press.
Wed, 11 Aug 2010 15:54:06 GMT
12 EDGE Fund Applications Approved to Advance to Second Phase of 2010 Funding Process
Proposals include projects in biotechnology, information technology, telecommunications, sensor technology, weather science and energy.
OKLAHOMA CITY, Okla., July 20 (SEND2PRESS NEWSWIRE) -- The Economic Development Generating Excellence Policy Board announced that 12 pre-proposal applications from an initial field of 62 have been approved to advance to the next step in the 2010 funding evaluation process. This year represents the third round of funding disbursement from the EDGE fund; in 2009, five awards were granted totaling $7.5 million. This year, around $6.5 million will be available for award distribution.
The 12 applicants are being asked to submit full proposals, due Sept. 1, 2010. This year's proposals include projects in biotechnology, information technology/telecommunications, sensor technology, weather science and energy, with several projects overlapping into multiple categories.
"Members of the EDGE Policy Board were very pleased with the high quality of this year's proposals. Each year's submissions have grown in significance and merit, and there were many excellent proposals among those who didn't advance," said Paul Risser, executive director of the EDGE Policy Board.
"With fewer dollars available from the EDGE endowment this year, the competition will be even more intense among the final few projects selected for funding. We can't overlook the need to grow the EDGE Endowment Fund to its full $1 billion total; at that level, we will be able to support many more of the top-tier projects that are going unfunded. Obviously the more innovation and technology EDGE can fund, the more businesses and jobs and wealth we'll be able to create for Oklahoma."
For the 2010 funding process, the following principal investigators have been invited to submit full proposals:
Biotechnology:
* Robert Floyd (Otologic Pharmaceutics) - Preclinical investigation of HPN-07 and NAC for the prevention and treatment of acute noise induced hearing loss
* William Hildebrand (Pure Protein, LLC) - Pure Protein, L.L.C.: EDGE-Enabled Expansion of Protein-Based Transplantation Products
* James Long (VADovations, Inc) - Development of a miniature blood pump
* Anne Perira (Biolytx Pharmaceuticals Corporation) - New drugs for Bad Bugs
* Donald Smith (Smith Algae BioFeeds and BioFuels) - Smith Algae BioFeeds and BioFuels: A Commercial Demonstration of CO2 to Algae as Cattle Feed for Heart Healthy Beef.
Energy:
* C. Drew Tait (Triarii Scientific LLC) - The Electromechanical Battery: A Disruptive Advance Technology that Changes the Energy Paradigm.
Information Technology/ Telecommunications:
* Max Doleh (Sigma Blood Systems, LLC) - Development of Integrated Blood Processing Solutions for Blood Centers
* D. Noah Roberts (Docvia LLC) - Oklahoma Emergency Health Registry Consortium.
Sensor Technology:
* Allen Apblett (Oklahoma State University) - Commercialization of Improvised Explosive Sensing Technology
* Nicholas Materer (SensorCor) - Commercialization of Passive Wireless Corrosion Sensors
* Jeff Wilson (Contineo Robotics) - Robotic Sensor Systems.
Weather Science:
* Allyson Turnbull (Enterprise Electronics Corporation) - Development, Manufacturing, and Support of Low Cost Doppler Weather Radars in Oklahoma.
The number and size of awards will be determined by the EDGE Policy Board which is chaired by Gary W. Derrick and consists of Thomas Kupiec Ph.D., Ken Levit, Gregory McKenzie, Bond Payne, and Stephen Prescott, M.D. The EDGE Endowment Fund is managed by a legislatively-mandated Board of Investors which certifies the amount of funds available each year to the EDGE Policy Board, which in turn, determines how the money will be allocated.
Established by Governor Henry in 2004, the mission of EDGE is to bolster Oklahoma's long-term economic growth by investing the earnings from the EDGE endowment in the state's knowledge infrastructure. EDGE investments are specifically directed toward Oklahoma-based projects that have the potential to expand the number of researchers, technicians, support services and related activity within the state; increase the formation and growth of advanced technology companies; leverage additional funding through federal research grants or private investment; and improve the health and quality of life for Oklahoma.
More information on EDGE fund: www.ok.gov/edge/.
NEWS SOURCE: Economic Development Generating Excellence Policy Board
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: Economic Development Generating Excellence Policy Board, Economic Development, Send2Press.
Tue, 20 Jul 2010 14:13:25 GMT
BusinessCashAdvance.com Offers Alternative Financing to SBA Business Loans
CORAL SPRINGS, Fla., June 25 (SEND2PRESS NEWSWIRE) -- On April 15, President Barack Obama signed legislation to add $80 million to the Small Business Association (SBA) business loan programs, and effectively extend stimulus benefits through the end of May. But a recent study suggests that a significant majority of small business owners will remain uninterested. Instead, many are seeking financing alternatives, says BusinessCashAdvance.
According to the Discover Small Business Watch, seventy percent of owners say that the recent federal stimulus efforts have had no impact on their businesses. Moreover, 91 percent of the small business owners surveyed stated that they have never applied for an SBA loan. This is up 1 percent from October 2009.
Of those who have never applied for an SBA loan, 54 percent say they did not need one; 13 percent would rather use personal assets, 13 percent received a business loan from another source, 11 percent are unfamiliar with the programs and 6 percent say it takes too much time. According to the survey, 61 percent of small business owners are "not very likely" or "not at all likely" to apply for a SBA loan even if they are easier to obtain.
In order to secure the operational capital they need to keep their businesses running smoothly, many small business owners have sought "alternative" methods of financing. This includes relying on personal assets, obtaining a private loan, or seeking asset-based lending arrangements, such as invoice factoring and business cash advances, based on future credit card purchases.
With 41 percent of small business owners who stated that the economy has had a negative impact on their business expecting that the recovery take more than a year, and with many putting their plans for hiring or expanding on hold, it may be a while before small businesses bring their banking to the banks.
About BusinessCashAdvance:
Founded by financial professionals, BusinessCashAdvance.com provides unsecured cash advances for small business. Financing companies in a broad spectrum of industries, it has helped retail stores, automotive shops, beauty salons, medical practices, florists, pet stores, restaurants, and others. A free application is available online at www.businesscashadvance.com or by calling 866-411-0606.
NEWS SOURCE: BusinessCashAdvance
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2010 Neotrope® News Network - all rights reserved.
TAGS: BusinessCashAdvance, Banking and Finance, Send2Press.
Fri, 25 Jun 2010 13:03:31 GMT
Epeius Biotechnologies to Partner at BIO Investor Forum
SAN FRANCISCO, Calif., Oct. 20 (SEND2PRESS NEWSWIRE) -- Epeius Biotechnologies Corporation, an emerging leader in the field of targeted genetic medicine, announced today that Frederick L. Hall, President and CEO, and Dr. Erlinda M. Gordon, Medical Director, will be participating in the 8th Annual BIO Investor Forum being held October 28-29, 2009, at the Palace Hotel in San Francisco. Participating companies that are poised for leadership status in areas of therapeutic innovation are chosen through a competitive screening process, with input by an advisory committee comprised of members from top-tier firms focused on investing and banking in the life sciences industry.
The selection of Epeius Biotechnologies as an investment opportunity was based on the accomplishment of significant clinical development milestones with its lead oncology product, Rexin-G, a tumor-targeted anti-cancer agent that is approved for use against all solid tumors by the Philippine FDA, and has recently received both Orphan Drug priorities and Fast Track designation by the U.S. FDA.
Epeius Biotechnologies is among a select group of companies which are recognized as those that are creating real value through development-stage programs with near-term clinical catalysts. According to the top-tier investor forum advisory committee, "These are the companies that will help drive the investment and deal making in the life sciences sector and global innovation in healthcare."
This prestigious forum provides an opportunity for senior management of Epeius Biotechnologies to showcase the remarkable clinical development of Rexin-G®, as stand-alone therapy for otherwise intractable metastatic cancers, and to partner with savvy investors that are capable of expediting the development of Rexin-G in the larger global market.
About Epeius Biotechnologies:
Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its leading oncology products and its tumor-targeted delivery systems.
To learn more about our pipeline of proprietary biotechnologies currently available for clinical development and/or new product development, please visit us at www.epeiusbiotech.com.
NEWS SOURCE: Epeius Biotechnologies Corporation
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: Epeius Biotechnologies Corporation, Funding and Investment, Send2Press.
Tue, 20 Oct 2009 13:17:36 GMT
CityMade, Inc. Announces Direct Public Offering
BUFFALO, N.Y., April 14 (SEND2PRESS NEWSWIRE) -- CityMade, Inc. today announced its direct public offering (DPO) of 800,000 shares of common stock that are being offered at U.S. $1.25 per share. This ground-floor investment opportunity is available to current customers, affiliate partners and the public.
A DPO is a pioneering form of financing and an innovative, cost-effective way for an established business to acquire needed expansion capital. In turn, it provides investors an affordable opportunity for a minimum investment of $300.
CityMade filed a Form D with the Securities and Exchange Commission (SEC) detailing information about the firm and the offering. The company also filed an Issuer Statement and Small Corporate Offering Registration relating to these securities with the State of New York Attorney General's office.
"CityMade has strategically positioned itself for aggressive growth over the next three years," CityMade president, Gary Steszewski, says. "We have diversified our business model to perform well, despite the dramatic economic downturn. We doubled our sales to $1.3 million in three years and project sales will more than double again in the next two years alone."
Tom Grifasi, Director of Investor Communications with Direct Public Offering Services, the firm that assisted CityMade with the preparation of its DPO, pointed out that, "CityMade is increasing its market size by more than 30 times in 2009 alone. And, with an established, proven business model and the reach and presence of CityMade's domains online, this is an investment opportunity worth considering."
Proceeds from the DPO will be used to provide working capital to expand on the success achieved by its original website and to multiply that success by expanding into 100 or more new cities within the next five years to create an international marketplace for recognized regional products "made in" cities around the world. CityMade currently owns the domain names to 140 domestic and international cities featuring the "made in" concept.
About CityMade, Inc.
Founded in 1999, CityMade is a global marketing company that specializes in sales of regional products from: Buffalo, NY; Syracuse, NY; Rochester, NY; Philadelphia; Baltimore; and Washington D.C. Five additional cities: Boston, Cleveland, New York, Pittsburgh, and Toronto are slated for launch in 2009.
CityMade also provides integrated commercial operations services on behalf of other business clients through its eCommerce, Order Fulfillment and Logistics Division.
CityMade has been recognized by Key Bank and the Buffalo Niagara Partnership in 2008 as the Honoring Excellence Most Innovative Company of the Year and in 2007 as the Honoring Excellence Business of the Year.
In addition to providing gifts and products directly to wholesale and retail consumers, CityMade has developed affiliate-gifting programs that may be integrated by corporations, retailers and other entities. CityMade's affiliate partners include Wegmans Markets; Lornamead/Yardley of London; Milk-Bone/DelMonte Foods; and NanoDynamics/NDMX Golf among others.
The company's prospectus is available by registering online at: www.citymade.com/dpo/. Inquiries may be sent via email to: dposhare@citymade.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
All trademarks and service marks are the property of the respective parties.
NEWS SOURCE: CityMade, Inc.
This story was issued by Send2Press® Newswire on behalf of the news source and is Copyright © 2009 Neotrope® News Network - all rights reserved.
TAGS: CityMade, Inc., Funding and Investment, Send2Press.
Tue, 14 Apr 2009 17:50:30 GMT
|
